Pulse Biosciences, INC Form 4 insider transactions

Pulse Biosciences director Robert Duggan acquired additional shares of common stock through open market purchases, increasing his total holdings.

Mitchell E. Levinson, Chief Strategy Officer of Pulse Biosciences, acquired common stock and warrants through the company's rights offering on September 24, 2024.

Paul A. Laviolette, a director of Pulse Biosciences, acquired stock options to purchase 250,000 shares of common stock on August 9, 2024.

Manmeet Singh Soni, a director of Pulse Biosciences, acquired 200,000 stock options on August 9, 2024.

Director Mahkam Zanganeh acquired 200,000 stock options in Pulse Biosciences, Inc. on August 9, 2024.

Pulse Biosciences CEO, Barrett Burke Thomas, reports acquiring and disposing of common stock and warrants at a price of $11 on July 19, 2024.

Director Mahkam Zanganeh acquired Pulse Biosciences common stock and warrants through the exercise of subscription rights in a previously announced rights offering.

Robert Duggan, a director and 10% owner of Pulse Biosciences, acquired additional common stock and warrants through the company's rights offering.

Kevin Patrick Danahy, Chief Commercial Officer of Pulse Biosciences, acquired common stock and warrants through the exercise of subscription rights in a previously announced rights offering.

Mitchell E. Levinson, Chief Strategy Officer of Pulse Biosciences, acquired common stock and warrants through a rights offering, increasing his and related parties' holdings.

Pulse Biosciences' CEO, Burke Thomas Barrett, acquired common stock and warrants through the company's rights offering on July 3, 2024.

Director Mahkam Zanganeh acquired stock options for Pulse Biosciences, Inc. on June 6, 2024.

Director Richard van den Broek of Pulse Biosciences, Inc. acquired stock options on June 6, 2024.

Director Manmeet Singh Soni acquired 20,000 stock options in Pulse Biosciences, Inc. on June 6, 2024.

Robert W. Duggan, a director and 10% owner of Pulse Biosciences, Inc., was granted stock options to purchase 36,247 shares of common stock on June 6, 2024.

Pulse Biosciences CEO Thomas Barrett was granted stock options for 1,400,000 shares on May 12, 2024, with vesting conditions tied to service and market capitalization milestones.

Pulse Biosciences CEO, Burke Thomas Barrett, purchased 10,000 shares of the company's common stock at a price of $8.56 per share on May 20, 2024.